PLSE
Pulse Biosciences, Inc.
$28.68
+1.30
(+4.75%)
Mkt Cap
1.98B
Volume
320,750
52W Range
12.56-31
Sector
Healthcare
Beta
1.65
EPS (TTM)
-1.09
P/E Ratio
-12.71
Revenue (TTM)
751,000
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 350,000 | 0 | 0 | 700,000 | 1.42M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.78M) | (53.59M) | (42.21M) | (58.51M) | (63.66M) | (49.74M) | (45.99M) | (37.55M) | (25.57M) | (9.52M) | (2.81M) | (474,857) |
| EPS | -1.08 | -0.92 | -0.88 | -1.72 | -2.28 | -2.14 | -2.22 | -2.20 | -1.73 | -0.86 | -0.37 | -0.19 |
| Free Cash Flow | (54.44M) | (36.47M) | (33.16M) | (47.41M) | (54.53M) | (35.81M) | (34.79M) | (24.17M) | (13.64M) | (8.12M) | (3.40M) | (252,000) |
| FCF / Share | -0.81 | -0.62 | -0.69 | -1.40 | -1.95 | -1.54 | -1.68 | -1.42 | -0.92 | -0.74 | -0.45 | -0.10 |
| Operating CF | (54.12M) | (36.34M) | (33.04M) | (47.01M) | (54.10M) | (35.37M) | (34.19M) | (23.90M) | (11.09M) | (8.05M) | (3.32M) | (173,143) |
| Total Assets | 96.11M | 132.46M | 59.15M | 77.88M | 54.25M | 41.29M | 41.91M | 70.64M | 49.82M | 26.31M | 14.33M | 17.90M |
| Total Debt | 7.53M | 8.90M | 9.14M | 75.96M | 11.25M | 11.36M | 6.72M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 80.73M | 118.04M | 44.37M | 61.14M | 28.61M | 12.46M | 6.90M | 51.10M | 3.39M | 2.09M | 3.61M | 7.01M |
| Book Value | 80.66M | 114.86M | 44.36M | (2.25M) | 35.69M | 22.89M | 30.74M | 66.33M | 45.99M | 25.30M | 13.67M | 16.07M |
| Return on Equity | -0.90 | -0.47 | -0.95 | N/A | -1.78 | -2.17 | -1.50 | -0.57 | -0.56 | -0.38 | -0.21 | -0.03 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 401,000 | 264,000 | 86,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (18.58M) | (17.43M) | (19.39M) | (19.17M) | (16.80M) | (19.39M) | (12.68M) | (11.38M) | (10.14M) | (11.93M) | (10.57M) | (9.91M) |
| EPS | -0.26 | -0.26 | -0.29 | -0.28 | -0.25 | -0.33 | -0.21 | -0.20 | -0.18 | -0.22 | -0.19 | -0.22 |
| Free Cash Flow | (14.63M) | (14.86M) | (13.10M) | (12.91M) | (13.57M) | (9.20M) | (9.06M) | (8.42M) | (9.79M) | (6.82M) | (10.51M) | (9.22M) |
| FCF / Share | -0.22 | -0.22 | -0.19 | -0.19 | -0.20 | -0.16 | -0.15 | -0.15 | -0.18 | -0.12 | -0.19 | -0.21 |
| Operating CF | (14.60M) | (14.76M) | (13.04M) | (12.81M) | (13.52M) | (9.14M) | (9.02M) | (8.39M) | (9.78M) | (6.78M) | (10.49M) | (9.20M) |
| Total Assets | 81.62M | 96.11M | 108.77M | 120.25M | 133.38M | 132.46M | 93.05M | 40.43M | 49.16M | 59.15M | 65.94M | 74.76M |
| Total Debt | 7.16M | 7.53M | 7.89M | 8.24M | 8.58M | 8.90M | 8.37M | 8.64M | 8.90M | 9.14M | 9.38M | 9.62M |
| Cash & Equiv | 68.32M | 80.73M | 95.21M | 106.35M | 119.28M | 118.04M | 79.03M | 26.20M | 34.88M | 44.37M | 50.39M | 58.75M |
| Book Value | 66.30M | 80.66M | 92.69M | 104.49M | 118.45M | 114.86M | 79.13M | 26.97M | 36.29M | 44.36M | 52.15M | 60.50M |
| Return on Equity | -0.28 | -0.22 | -0.21 | -0.18 | -0.14 | -0.17 | -0.16 | -0.42 | -0.28 | -0.27 | -0.20 | -0.16 |
PLSE News
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
Pulse Biosciences Q1 Earnings Call Highlights
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference